发布求助
文献互助 智能选刊 最新文献

Pharmadeals Review最新文献

筛选
英文 中文
Eli Lilly Joins ImmunoGen’s List of Big Pharma Collaborators 礼来加入免疫原的大型制药合作伙伴名单
Pharmadeals Review Pub Date : 2012-06-01 DOI: 10.3833/pdr.v2012i1.1648
Heather Cartwright
{"title":"Eli Lilly Joins ImmunoGen’s List of Big Pharma Collaborators","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i1.1648","DOIUrl":"https://doi.org/10.3833/pdr.v2012i1.1648","url":null,"abstract":"Eli Lilly has gained rights to use ImmunoGen’s maytansinoid targeted antibody payload (TAP) technology to develop a specified number of antibody-drug conjugates for the potential treatment of cancer. ImmunoGen will receive US$20 M upfront and could receive up to US$200 M in milestone payments for each licence taken as well as royalties on sales of any resulting products. With this deal, Eli Lilly has joined ImmunoGen’s list of TAP partners that includes Amgen, Bayer Healthcare, Roche, Novartis and Sanofi.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89161478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
InterMune Divests Declining Actimmune® to Focus on Esbriet® InterMune撤资减少actimune®专注于Esbriet®
Pharmadeals Review Pub Date : 2012-05-28 DOI: 10.3833/pdr.v2012i5.1746
Heather Cartwright
{"title":"InterMune Divests Declining Actimmune® to Focus on Esbriet®","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i5.1746","DOIUrl":"https://doi.org/10.3833/pdr.v2012i5.1746","url":null,"abstract":"InterMune has agreed to sell the rights to Actimmune® (interferon gamma-1b), which is approved for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis, to Vidara Therapeutics International for US$55 M in cash plus royalties over 2 years. The proceeds from the transaction will help InterMune to invest in the registration and commercialisation of its idiopathic pulmonary fibrosis drug Esbriet® (pirfenidone) in Europe and elsewhere.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89536788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Agilent Technologies Agrees to Acquire Dako for US$2.2 B in its Largest Deal to Date 安捷伦科技同意以22亿美元收购Dako，这是其迄今为止最大的一笔交易
Pharmadeals Review Pub Date : 2012-05-24 DOI: 10.3833/PDR.V2012I5.1744
Heather Cartwright
{"title":"Agilent Technologies Agrees to Acquire Dako for US$2.2 B in its Largest Deal to Date","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I5.1744","DOIUrl":"https://doi.org/10.3833/PDR.V2012I5.1744","url":null,"abstract":"Agilent Technologies has agreed to buy the Danish cancer diagnostics company Dako, which is currently owned by the Swedish private equity group EQT Partners, for US$2.2 B. The acquisition, which represents the largest deal in Agilent’s history, is the company’s latest attempt to expand its life sciences business and will complement its existing diagnostics portfolio.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86075697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GSK to Acquire Full Control of its Proteomics Partner Cellzome GSK将收购其蛋白质组学合作伙伴Cellzome的全部控制权
Pharmadeals Review Pub Date : 2012-05-21 DOI: 10.3833/PDR.V2012I5.1743
Heather Cartwright
{"title":"GSK to Acquire Full Control of its Proteomics Partner Cellzome","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I5.1743","DOIUrl":"https://doi.org/10.3833/PDR.V2012I5.1743","url":null,"abstract":"GlaxoSmithKline (GSK) has agreed to acquire the 80.02% of its proteomics research partner Cellzome that it does not already own for £61 M (US$98 M) in cash. The acquisition will expand GSK’s existing drug discovery platform and add to its capacity to characterise drug targets. Simultaneously, the two parties intend to create a spin-off company, which would hold the rights to certain Cellzome assets and activities that GSK does not wish to progress.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88391403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abbott to Acquire Global Rights to Action Pharma’s Phase II Acute Kidney Injury Drug 雅培将获得Action Pharma的II期急性肾损伤药物的全球权利
Pharmadeals Review Pub Date : 2012-05-14 DOI: 10.3833/PDR.V2012I5.1742
Heather Cartwright
{"title":"Abbott to Acquire Global Rights to Action Pharma’s Phase II Acute Kidney Injury Drug","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I5.1742","DOIUrl":"https://doi.org/10.3833/PDR.V2012I5.1742","url":null,"abstract":"Abbott is to acquire worldwide development and commercialisation rights to Action Pharma’s AP214, an alpha-MSH (melanocyte-stimulating hormone) peptide derivative in Phase IIb development for the prevention of acute kidney injury associated with major cardiac surgery, for a one-time cash payment of US$110 M. Zealand Pharma, from which Action licensed the SIP® (structure induced probe) peptide modification technology that has been used in the development of AP214, also stands to benefit from the deal.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74937878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GSK Divests its Final Tranche of Non-Core OTC Brands to Aspen Pharmacare 葛兰素史克将其非核心OTC品牌的最后一部分出售给Aspen Pharmacare
Pharmadeals Review Pub Date : 2012-04-30 DOI: 10.3833/pdr.v2012i4.1731
Heather Cartwright
{"title":"GSK Divests its Final Tranche of Non-Core OTC Brands to Aspen Pharmacare","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i4.1731","DOIUrl":"https://doi.org/10.3833/pdr.v2012i4.1731","url":null,"abstract":"GlaxoSmithKline has agreed to sell a portfolio of international OTC brands, excluding the troubled anti-obesity drug alli® (orlistat, 60 mg), to South Africa’s Aspen Pharmacare for £164 M (US$263 M). The divested brands generated sales of approximately £60 M (US$94 M) in 2011. The acquisition will drive growth for Aspen in Latin America and Southeast Asia.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84354104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sanofi Augments its Biosurgery Unit with Pluromed Acquisition 赛诺菲通过收购plromed扩大其生物外科部门
Pharmadeals Review Pub Date : 2012-03-26 DOI: 10.3833/pdr.v2012i3.1705
Heather Cartwright
{"title":"Sanofi Augments its Biosurgery Unit with Pluromed Acquisition","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i3.1705","DOIUrl":"https://doi.org/10.3833/pdr.v2012i3.1705","url":null,"abstract":"Sanofi has agreed to buy the US medical device company Pluromed in order to strengthen the biosurgery portfolio it gained via its takeover of Genzyme in 2011. With the acquisition, Sanofi will gain Pluromed’s biocompatible reverse thermosensitive polymer technology, Rapid Transition Polymers™, and LeGoo® gel, which was approved by the US FDA in September 2011 and which provides temporary blood vessel occlusion during surgery","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82381905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shire Bolsters its Haematology Business with US$325 M FerroKin BioSciences Acquisition Shire以3.25亿美元收购FerroKin BioSciences加强其血液学业务
Pharmadeals Review Pub Date : 2012-03-20 DOI: 10.3833/PDR.V2012I3.1702
Heather Cartwright
{"title":"Shire Bolsters its Haematology Business with US$325 M FerroKin BioSciences Acquisition","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I3.1702","DOIUrl":"https://doi.org/10.3833/PDR.V2012I3.1702","url":null,"abstract":"Shire has moved to strengthen its haematology franchise by agreeing to acquire FerroKin BioSciences for up to US$325 M. With the acquisition, Shire will gain FerroKin’s iron chelator FBS0701, which is in Phase II development for the treatment of iron overload due to chronic blood transfusions. Shire will pay US$100 M upfront in cash and up to US$225 M in potential clinical development, regulatory and commercial milestones related to the drug, which could be launched as early as 2016.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90608387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mersana Therapeutics Raises Profile with Antibody-Drug Conjugate Collaboration with Endo Mersana Therapeutics与Endo的抗体-药物偶联合作提高了知名度
Pharmadeals Review Pub Date : 2012-03-16 DOI: 10.3833/PDR.V2012I3.1700
Heather Cartwright
{"title":"Mersana Therapeutics Raises Profile with Antibody-Drug Conjugate Collaboration with Endo","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I3.1700","DOIUrl":"https://doi.org/10.3833/PDR.V2012I3.1700","url":null,"abstract":"Mersana Therapeutics has formed a collaboration with Endo Pharmaceuticals to develop next-generation antibody-drug conjugates (ADCs) against a single, undisclosed cancer target. Mersana will combine its Fleximer® conjugation technology with anticancer antibodies discovered by Endo to produce Fleximer-ADC candidates for development, manufacturing and commercialisation by Endo. With this deal, Mersana has emerged as a competitor of Seattle Genetics and ImmunoGen in the development of ADCs.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74571773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Daiichi Sankyo and GSK to Establish Vaccines Joint Venture in Japan Daiichi Sankyo和GSK将在日本成立疫苗合资企业
Pharmadeals Review Pub Date : 2012-03-14 DOI: 10.3833/PDR.V2012I3.1699
Heather Cartwright
{"title":"Daiichi Sankyo and GSK to Establish Vaccines Joint Venture in Japan","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I3.1699","DOIUrl":"https://doi.org/10.3833/PDR.V2012I3.1699","url":null,"abstract":"Daiichi Sankyo and GlaxoSmithKline have agreed to form a 50-50 joint venture for the development and distribution of vaccines in Japan. The joint venture, which will be named Japan Vaccine and which will commence business in July 2012 with an initial capitalisation of ¥100 M (US$1.2 M), will inherit development and commercialisation rights to prophylactic vaccines from both parent companies. Its business will later be expanded as new vaccines from the pipeline are approved.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"94 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75240415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信